동맥관 개존이 있는 미숙아에서 혈장 B-type natriuretic peptide 검사의 임상 적용

키워드

참고문헌 (58)

1. Stamps JK, "Natriuretic peptides ... they’re not just for adults anymore", Curr Opin Cardiol, 24, pp.103~104 (2009)
2. Favilli S, "The use of B-type natriuretic peptide in paediatric patients: a review of literature", J Cardiovasc Med (Hagerstown), 10, pp.298~302 (2009)
3. Maher KO, "B-type natriuretic peptide in the emergency diagnosis of critical heart disease in children", Pediatrics, 121, pp.e1484~e1488 (2008)
4. Westerlind A, "Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy", Acta Paediatr, 93, pp.340~345 (2004)
5. Law YM, "Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study", J Am Coll Cardiol, 54, pp.1467~1475 (2009)
6. Yoon YS, "Usefulness of plasma B-type natriuretic peptide assay as a screening tool for infants with suspected congenital heart disease", J Korean Soc Neonatol, 12, pp.141~149 (2005)
7. Ko HK, "Utility of the rapid B-type natriuretic peptide assay for detection of cardiovascular problems in newborn infants with respiratory difficulties", Neonatology, 94, pp.16~21 (2008)
8. Baptista MJ, "Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn", Pediatrics, 115, pp.1111~ (2005)
9. Reynolds EW, "Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn", Pediatrics, 114, pp.1297~1304 (2004)
10. Vijlbrief DC, "B-type natriuretic peptide and rebound during treatment for persistent pulmonary hypertension", J Pediatr, 160, pp.111~115 (2012)
11. Das BB, "Natriuretic peptides in cardiovascular diseases of fetus, infants and children", Cardiovasc Hematol Agents Med Chem, 7, pp.43~51 (2009)
12. El-Khuffash A, "Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates?", Arch Dis Child Fetal Neonatal Ed, 92, pp.F320~F324 (2007)
13. Nash PL, "Brain type natriuretic peptide", Neonatal Netw, 27, pp.343~346 (2008)
14. Vijlbrief DC, "Use of cardiac biomarkers in neonatology", Pediatr Res, 72, pp.337~343 (2012)
15. Zonnenberg I, "The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review", Acta Paediatr, 101, pp.247~251 (2012)
16. Evans N, "Preterm patent ductus arteriosus: should we treat it?", J Paediatr Child Health, 48, pp.753~758 (2012)
17. Clyman RI, "Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?", Semin Perinatol, 36, pp.123~129 (2012)
18. Guimaraes H, "Non-steroid anti-inflammatory drugs in the treatment of patent ductus arteriosus in European newborns", J Matern Fetal Neonatal Med, 22(Suppl 3), pp.77~80 (2009)
19. Hoellering AB, "The management of patent ductus arteriosus in Australia and New Zealand", J Paediatr Child Health, 45, pp.204~209 (2009)
20. Benitz WE, "Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?", J Perinatol, 30, pp.241~252 (2010)
21. Evans N, "Diagnosis of the preterm patent ductus arteriosus: clinical signs, biomarkers, or ultrasound?", Semin Perinatol, 36, pp.114~122 (2012)
22. Kluckow M, "Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation", J Pediatr, 127, pp.774~779 (1995)
23. Evans N, "Longitudinal changes in the diameter of the ductus arteriosus in ventilated preterm infants: correlation with respiratory outcomes", Arch Dis Child Fetal Neonatal Ed, 72, pp.F156~F161 (1995)
24. Kangawa K, "Structure and function of the natriuretic peptide family", Nippon Rinsho, 62(Suppl 9), pp.10~17 (2004)
25. Matsuo H, "Discovery of a natriuretic peptide family and their clinical application", Can J Physiol Pharmacol, 79, pp.736~740 (2001)
26. Sudoh T, "A new natriuretic peptide in porcine brain", Nature, 332, pp.78~81 (1988)
27. Saito Y, "Brain natriuretic peptide is a novel cardiac hormone", Biochem Biophys Res Commun, 158, pp.360~368 (1989)
28. Yasue H, "Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of a-type natriuretic peptide in normal subjects and patients with heart failure", Circulation, 90, pp.195~203 (1994)
29. Nakagawa O, "Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload", J Clin Invest, 96, pp.1280~1287 (1995)
30. Witthaut R, "Science review: natriuretic peptides in critical illness", Crit Care, 8, pp.342~349 (2004)
31. Oishi PE, "BNP for pediatrics--not quite ready for primetime", Pediatr Crit Care Med, 7, pp.388~389 (2006)
32. Socrates T, "B-type natriuretic peptide in children: step by step", J Am Coll Cardiol, 54, pp.1476~1477 (2009)
33. Holmström H, "Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants", Acta Paediatr, 90, pp.184~191 (2001)
34. Choi BM, "Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants", Pediatrics, 115, pp.e255~e261 (2005)
35. Sanjeev S, "Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates", J Perinatol, 25, pp.709~713 (2005)
36. 김준식, "B-Type Natriuretic Peptide Assay for the Diagnosis and Prognosis of Patent Ductus Arteriosus in Preterm Infants", Korean Circulation Journal, 42(3), pp.192~196 (2012), 대한심장학회
37. Mine K, "B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants", Acta Paediatr, 102, pp.e347~e352 (2013)
38. Chen S, "How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude?", J Perinatol, 30, pp.780~785 (2010)
39. Kalra VK, "Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus", Ann Clin Lab Sci, 41, pp.131~137 (2011)
40. da Graca RL, "Longitudinal changes of brain-type natriuretic peptide in preterm neonates", Pediatrics, 117, pp.2183~2189 (2006)
41. Lee HS, "Usefulness of B-type natriuretic peptide assay in predicting symptomatic patent ductus arteriosus in preterm infants", J Korean Soc Neonatol, 11, pp.44~53 (2004)
42. Flynn PA, "The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates", J Pediatr, 147, pp.38~42 (2005)
43. Mannarino S, "BNP concentrations and cardiovascular adaptation in preterm and fullterm newborn infants", Early Hum Dev, 86, pp.295~298 (2010)
44. Kazanci SY, "The relation between brain natriuretic peptide and patent ductus arteriosus in premature infants", Turk Pediatri Arsivi, 47, pp.90~94 (2012)
45. Lee JH, "Can early B-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants?", Neonatology, 103, pp.118~122 (2013)
46. Puddy VF, "Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants", Clin Sci (Lond), 103, pp.75~77 (2002)
47. Attridge JT, "B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus", Arch Dis Child Fetal Neonatal Ed, 94, pp.F178~F182 (2009)
48. Fowlie PW, "Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants", Cochrane Database Syst Rev, (7), pp.CD000174~ (2010)
49. Ohlsson A, "Ibuprofen for the prevention of patent ductus arteriosus in preterm and", or low birth weight infants, 2011, pp.(7), CD004213~
50. Evans N, "Current controversies in the diagnosis and treatment of patent ductus arteriosus in preterm infants", Adv Neonatal Care, 3, pp.168~177 (2003)
51. Schmidt B, "Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP)", J Pediatr, 148, pp.730~734 (2006)
52. Hammerman C, "The silent ductus: its precursors and its aftermath", Pediatr Cardiol, 7, pp.121~127 (1986)
53. Cooke L, "Indomethacin for asymptomatic patent ductus arteriosus in preterm infants", Cochrane Database Syst Rev, (2), pp.CD003745~ (2003)
54. Su BH, "Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial", Arch Dis Child Fetal Neonatal Ed, 93, pp.F94~F99 (2008)
55. Czernik C, "B-type natriuretic peptide to predict ductus intervention in infants <28 weeks", Pediatr Res, 64, pp.286~290 (2008)
56. Malviya MN, "Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants", Cochrane Database Syst Rev, 3, pp.CD003951~ (2013)
57. Narayanan M, "Prophylactic indomethacin: factors determining permanent ductus arteriosus closure", J Pediatr, 136, pp.330~337 (2000)
58. Hsu JH, "B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus", J Pediatr, 157, pp.79~84 (2010)

관련 논문AI추천